GlassScriptPhysician profile
Sen B Lai
NPI 1740227040
$3,557.91
in general payments reported to CMS, 2019-2025
23 companies · $915 in 2025
The $915 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.36 · 2020: $12.70 · 2021: $126 · 2022: $465 · 2023: $1,143 · 2024: $864 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $466.23 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $464.98 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $369.36 | 2021-2025 | |
| Novo Nordisk INC | $356.87 | 2022-2025 | Ozempic, Wegovy |
| Pfizer INC. | $341.54 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $294.15 | 2020-2025 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.04 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $190.14 | 2022-2023 | Verquvo |
| Amgen INC. | $188.41 | 2024-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.30 | 2022-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $107.67 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $107.59 | 2022-2025 | Eliquis, Camzyos |
| Abbvie INC. | $59.48 | 2023-2025 | |
| Gilead Sciences, INC. | $50.51 | 2022-2024 | |
| Lilly USA, LLC | $42.29 | 2022-2025 | Mounjaro, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $36.60 | 2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $31.99 | 2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $28.02 | 2024 | Amvuttra |
| Phathom Pharmaceuticals, INC. | $25.79 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $23.68 | 2025 | Shingrix |
| Shield Therapeutics INC | $23.50 | 2025 | |
| Heartflow, INC. | $17.71 | 2022 | |
| Baxter Healthcare | $16.06 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sen Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.